{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'assumed to be treatment-emergent. No formal hypothesis-testing of AE incidence rates will be', 'performed.', 'The causal relationship between the occurrence of an AE and the study treatment will be judged', 'by the Investigator as not related or related (see Section 12.1.4). In the event a patient', 'experiences repeat episodes of the same AE, then the event with the highest severity and/or', 'strongest causal relationship to treatment will be used for purposes of tabulations.', '13.7.2.3. Clinical Laboratory Data', 'Clinical laboratory values will be expressed using conventional International System of Units', '(SI) units.', 'For each treatment arm, the actual value and change from baseline (Day 1, prior to the first', 'administration of study treatment) to each on-study evaluation will be summarized for each', 'quantitative clinical laboratory parameter, including, but not limited to, hematology, clinical', 'chemistry, coagulation, and urinalysis. In the event of repeat values, the last non-missing value', 'per study day will be used. In the event that Day 1 data are unavailable for a given', 'patient/parameter, the screening value will substitute as the baseline value.', 'Severity of select clinical laboratory measures will be determined using NCI CTCAE criteria (eg,', 'those measures that have a corresponding NCI CTCAE grade classification). Laboratory test', 'results with NCI CTCAE Grades >3 will be presented in a by-patient data listing. Shift tables', 'that present changes from baseline to worst on-study values and from baseline to last on-study', 'values relative to NCI CTCAE classification ranges will be produced.', 'All laboratory data will be provided in by-patient data listings.', '13.7.2.4. Vital Signs and Physical Examinations', 'The actual value and change from baseline (Day 1, prior to the first administration of study', 'treatment) to each on-study evaluation will be summarized for vital signs including pulse rate,', 'temperature, systolic BP, diastolic BP, weight, and BSA. Shift tables that present changes from', 'baseline to worst on-study and last on-study ECOG performance status values will be produced.', 'Vital sign measurements and all physical examination findings will be presented in by-patient', 'data listings.', '13.7.2.5. Electrocardiogram', 'ECG results will be summarized descriptively, including heart rate and PR, QRS, QT, and QTc', 'intervals (calculated by the Fridericia correction formula (Fridericia 1920); intervals. Actual', 'values and changes from baseline will be reported for each study visit. ECG data for each patient', 'will be provided in a by-patient data listing.', '13.7.2.6. Ophthalmological Examinations', 'Ophthalmological examination findings will be summarized descriptively by visit and presented', 'in by-patient data listings.', 'Confidential', 'Page 102', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '13.7.2.7. Concomitant Medications', 'Concomitant medications will be coded using the World Health Organization Drug Dictionary', 'and will be summarized by Anatomic Therapeutic Chemical Classification System level 2', '(therapeutic level), level 4 (generic level), and standard names. Both prior and concomitant', 'medications will be included in by-patient data listings.', '13.8.', 'QoL Analyses', 'Patient-reported peripheral neuropathy will be assessed using the EORTC-QLQ-CIPN20', 'validated instrument. The actual value and change from baseline will be summarized using', 'descriptive statistics over time for each of the 3 EORTC-QLQ-CIPN20 subscale scores.', 'Treatment differences in change from baseline to each scheduled visit will be evaluated using a', 'linear mixed effects model with fixed effects of treatment arm, randomization stratification', 'factors, and the baseline value for the parameter in the model as a covariate, as well as random', 'effect of patients and repeated measures over time points.', '13.9.', 'Changes in the Conduct of the Study or Planned Analyses', 'All deviations from the final SAP will be documented and provided in the final CSR.', 'Confidential', 'Page 103', 'Version 4.0']\n\n###\n\n", "completion": "END"}